Cryo-Cell International Inc

Latest Report Overview

Cryo-Cell International Inc (CCEL) reported For the quarterly period ended August 31, 2026 (Issuer fiscal Q3 FY2026) revenue of $7.8 million with diluted EPS of $0.16 and net income of $1.3 million. Operating margin was 28.0%, and free cash flow was $1 million for the period. Operating performance during the third quarter demonstrated solid operational discipline, with operating income expanding to robust levels yielding an operating margin of 28.0% and free cash flow of $1,039,900. Management commentary emphasizes ongoing focus on processing efficiency and core banking volumes while supporting targeted investments in cellular therapy applications. The company's balance sheet reflects total debt of $8,638,000 and cash reserves of $1,425,700, underscoring the importance of steady operating cash generation to service liabilities and support ongoing capital requirements without straining liquidity.

Key Takeaways for Cryo-Cell International Inc

• Cryo-Cell reported Q3 FY2026 revenue of $7.82 million, flat year-over-year (-0.0%), accompanied by net income of $1.27 million and diluted EPS of $0.16.
• Gross margins expanded to 79.4% in Q3 FY2026, up from 77.0% in the prior-year period, reflecting favorable operating efficiencies and cost discipline.
• Operating profitability improved markedly, yielding an operating margin of 28.0% and operating cash flow of $1.14 million for the quarter.
• The balance sheet reflects total debt of $8.64 million compared to modest cash reserves of $1.43 million, maintaining a net debt position of $7.21 million.
• Free cash flow remained positive at $1.04 million for Q3, supporting liquidity alongside trailing twelve-month free cash flow of $4.65 million.

What Does Cryo-Cell International Inc Do?

Cryo-Cell International, Inc. operates as a cellular preservation and cord blood banking company, providing family and public cord blood and cord tissue stem cell cryopreservation services. The company processes and stores stem cells harvested from umbilical cord blood and tissue, which are utilized for potential future regenerative medicine and therapeutic applications. The primary customer base consists of expectant parents seeking to preserve their newborns' stem cells for potential medical treatments. Cryo-Cell markets its services directly to consumers as well as through healthcare professional channels, operating primarily within the United States alongside international licensing partners. Scale indicators include trailing twelve-month revenues of approximately $31.1 million, strong gross margins approaching 79%, and a specialized laboratory infrastructure designed to meet stringent regulatory standards for cellular storage. The company's unique value proposition combines state-of-the-art cryopreservation technology with comprehensive processing protocols and clinical trial engagements.

Growth Drivers for Cryo-Cell International Inc

• Expansion of direct-to-consumer marketing initiatives to capture a larger share of expectant parents.
• Strategic partnerships with OB/GYNs and healthcare professionals to drive institutional referrals.
• Development and advancement of proprietary cellular therapy applications and clinical collaborations.
• Optimization of laboratory processing efficiencies to support gross margin expansion.
• Geographic and international licensee expansion to tap into emerging overseas markets.